Urinary incontinence in men: current and developing therapy options

References

• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society. Neurourol Urodyn. 2002;21(2):167–178.
   PubMed Web of Science ®Google Scholar
• Markland AD, Goode PS, Redden DT, et al. Prevalence of urinary incontinence in men: results from the national health and nutrition examination survey. J Urol. 2010 Sep;184(3):1022–1027.
   PubMed Web of Science ®Google Scholar
• Lagro-Janssen TA, Hilkens CJ, Klaasen RI, et al. Greater emotional and social effect of urinary incontinence in men than women. J Am Geriatr Soc. 2008 Sep;56(9):1779–1781.
   PubMed Web of Science ®Google Scholar
• NICE. Male lower urinary tract symptoms. London: National Institute for Health and Care Excellence; 2010.
   Google Scholar
• Lucas MG, Bedretdinova D, Berghmans LC, et al. EAU guidelines - urinary incontinence. Arnhem: EAU; 2015. p. 6–90.
   Google Scholar
• NICE. Suspected cancer: recognition and referral. London: National Institute for Health and Care Excellence; 2015.
   Google Scholar
• Abrams PC, Cardozo L, Khoury S, et al. Incontinence. 5th international consultation on incontinence. Arnhem: European Association of Urology and International Consultation on Urological Diseases; 2013.
   Google Scholar
• Drake MJ, Chapple C, Sokol R, et al. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE study and NEPTUNE II open-label extension. Eur Urol. 2015 Feb;67(2):262–270.
   PubMed Web of Science ®Google Scholar
• Caulfield MP, Straughan DW, Cross AJ, et al. Cortical muscarinic receptor subtypes and Alzheimer’s disease. Lancet. 1982 Dec 4;2(8310):1277.
   PubMed Web of Science ®Google Scholar
• Abrams P, Andersson KE. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007 Nov;100(5):987–1006.
   PubMed Web of Science ®Google Scholar
• Hills CJ, Winter SA, Balfour JA. Tolterodine. Drugs. 1998 Jun;55(6):813–820. discussion 21–2.
   PubMed Web of Science ®Google Scholar
• Appell RA, Sand P, Dmochowski R, et al. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study. Mayo Clin Proc. 2001 Apr;76(4):358–363.
   PubMed Web of Science ®Google Scholar
• Diokno AC, Appell RA, Sand PK, et al. Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun;78(6):687–695.
   PubMed Web of Science ®Google Scholar
• Olshansky B, Ebinger U, Brum J, et al. Differential pharmacological effects of antimuscarinic drugs on heart rate: a randomized, placebo-controlled, double-blind, crossover study with tolterodine and darifenacin in healthy participants > or = 50 years. J Cardiovasc Pharmacol Ther. 2008 Dec;13(4):241–251.
   PubMed Web of Science ®Google Scholar
• Hsiao SM, Chang TC, Wu WY, et al. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome. J Obstet Gynaecol Res. 2011 Aug;37(8):1084–1091.
   PubMed Web of Science ®Google Scholar
• Abrams P, Kaplan S, De Koning Gans HJ, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol. 2006;175(3 Pt 1):999–1004. discussion 04.
   PubMed Web of Science ®Google Scholar
• Roehrborn CG, Kaplan SA, Jones JS, et al. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol. 2009 Feb;55(2):472–479.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA. 2006 Nov 15;296(19):2319–2328.
   PubMed Web of Science ®Google Scholar
• Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008 Sep;180(3):1034–1041.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Roehrborn CG, Chancellor M, et al. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the international prostate symptom score. BJU Int. 2008 Nov;102(9):1133–1139.
   PubMed Web of Science ®Google Scholar
• Chung DE, Te AE, Staskin DR, et al. Efficacy and safety of tolterodine extended release and dutasteride in male overactive bladder patients with prostates >30 grams. Urology. 2010 May;75(5):1144–1148.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Herschorn S, Abrams P, et al. Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration. BJU Int. 2010 Nov;106(9):1332–1338.
   PubMed Web of Science ®Google Scholar
• Haab F, Stewart L, Dwyer P. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol. 2004 Apr;45(4):420–429. discussion 29.
   PubMed Web of Science ®Google Scholar
• Haab F, Corcos J, Siami P, et al. Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study. BJU Int. 2006 Nov;98(5):1025–1032.
   PubMed Web of Science ®Google Scholar
• Schneider T, Marschall-Kehrel D, Hanisch JU, et al. Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients? Int J Clin Pract. 2010 Aug;64(9):1287–1293.
   PubMed Web of Science ®Google Scholar
• Ney P, Pandita RK, Newgreen DT, et al. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008 Apr;101(8):1036–1042.
   PubMed Web of Science ®Google Scholar
• Malhotra B, Guan Z, Wood N, et al. Pharmacokinetic profile of fesoterodine. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556–563.
   PubMed Web of Science ®Google Scholar
• Chapple C, Van Kerrebroeck P, Tubaro A, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol. 2007 Oct;52(4):1204–1212.
   PubMed Web of Science ®Google Scholar
• Kaplan SA, Schneider T, Foote JE, et al. Superior efficacy of fesoterodine over tolterodine extended release with rapid onset: a prospective, head-to-head, placebo-controlled trial. BJU Int. 2011 May;107(9):1432–1440.
   PubMed Web of Science ®Google Scholar
• Ginsberg D, Schneider T, Kelleher C, et al. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder. BJU Int. 2013 Aug;112(3):373–385.
   PubMed Web of Science ®Google Scholar
• Smulders RA, Krauwinkel WJ, Swart PJ, et al. Pharmacokinetics and safety of solifenacin succinate in healthy young men. J Clin Pharmacol. 2004 Sep;44(9):1023–1033.
   PubMed Web of Science ®Google Scholar
• Chapple CR, Rechberger T, Al-Shukri S, et al. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int. 2004 Feb;93(3):303–310.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Lisec M, Millard R, et al. Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder. J Urol. 2004 Nov;172(5 Pt 1):1919–1924.
   PubMed Web of Science ®Google Scholar
• Luo D, Liu L, Han P, et al. Solifenacin for overactive bladder: a systematic review and meta-analysis. Int Urogynecol J. 2012 Aug;23(8):983–991.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms–ASSIST, randomized controlled study. Urology. 2011;78(1):126–133.
   PubMed Web of Science ®Google Scholar
• Staskin D, Kay G, Tannenbaum C, et al. Trospium chloride has no effect on memory testing and is assay undetectable in the central nervous system of older patients with overactive bladder. Int J Clin Pract. 2010 Aug;64(9):1294–1300.
   PubMed Web of Science ®Google Scholar
• Fusgen I, Hauri D. Trospium chloride: an effective option for medical treatment of bladder overactivity. Int J Clin Pharmacol Ther. 2000 May;38(5):223–234.
   PubMed Web of Science ®Google Scholar
• Chancellor M, Boone T. Anticholinergics for overactive bladder therapy: central nervous system effects. CNS Neurosci Ther. 2012 Feb;18(2):167–174.
   PubMed Web of Science ®Google Scholar
• Cardozo L, Chapple CR, Toozs-Hobson P, et al. Efficacy of trospium chloride in patients with detrusor instability: a placebo-controlled, randomized, double-blind, multicentre clinical trial. BJU Int. 2000 Apr;85(6):659–664.
   PubMed Web of Science ®Google Scholar
• Dmochowski RR, Sand PK, Zinner NR, et al. Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar;71(3):449–454.
   PubMed Web of Science ®Google Scholar
• Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171(6 Pt 1):2311–2315. quiz 435.
   PubMed Web of Science ®Google Scholar
• MacDiarmid SA, Ellsworth PI, Ginsberg DA, et al. Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder. Urology. 2011 Jan;77(1):24–29.
   PubMed Web of Science ®Google Scholar
• Hughes KM, Lang JC, Lazare R, et al. Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers. Xenobiotica. 1992 Jul;22(7):859–869.
   PubMed Web of Science ®Google Scholar
• Nilvebrant L, Sparf B. Dicyclomine, benzhexol and oxybutynine distinguish between subclasses of muscarinic binding sites. Eur J Pharmacol. 1986 Apr 9;123(1):133–143.
   PubMed Web of Science ®Google Scholar
• Thuroff JW, Chartier-Kastler E, Corcus J, et al. Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol. 1998;16(Suppl 1):S48–S61.
   Google Scholar
• Versi E, Appell R, Mobley D, et al. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol. 2000;95(5):718–721.
   PubMed Web of Science ®Google Scholar
• Cartwright R, Srikrishna S, Cardozo L, et al. Patient-selected goals in overactive bladder: a placebo controlled randomized double-blind trial of transdermal oxybutynin for the treatment of urgency and urge incontinence. BJU Int. 2011 Jan;107(1):70–76.
   PubMed Web of Science ®Google Scholar
• Staskin DR, Dmochowski RR, Sand PK, et al. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr;181(4):1764–1772.
   PubMed Web of Science ®Google Scholar
• Kay G, Crook T, Rekeda L, et al. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur Urol. 2006 Aug;50(2):317–326.
   PubMed Web of Science ®Google Scholar
• Burgio KL, Goode PS, Johnson TM, et al. Behavioral versus drug treatment for overactive bladder in men: the male overactive bladder treatment in veterans (MOTIVE) trial. J Am Geriatr Soc. 2011 Dec;59(12):2209–2216.
   PubMed Web of Science ®Google Scholar
• MacDiarmid SA, Peters KM, Chen A, et al. Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study. Mayo Clin Proc. 2008;83(9):1002–1010.
   PubMed Web of Science ®Google Scholar
• NICE. Urinary incontinence in women. London: National Institute for Health and Care Excellence; 2013.
   Google Scholar
• Wagg A, Compion G, Fahey A, et al. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012 Dec;110(11):1767–1774.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013 Apr;189(4):1388–1395.
   PubMed Web of Science ®Google Scholar
• Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013 Feb;63(2):283–295.
   PubMed Web of Science ®Google Scholar
• Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013 Aug;82(2):313–320.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Khullar V, van Kerrebroeck P, et al. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Int J Clin Pract. 2013;67(7):619–632.
   PubMed Web of Science ®Google Scholar
• van Gelderen M, Tretter R, Meijer J, et al. Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men. Int J Clin Pharmacol Ther. 2014 Aug;52(8):693–701.
   PubMed Web of Science ®Google Scholar
• Nitti VW, Rosenberg S, Mitcheson DH, et al. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013;190(4):1320–1327.
   PubMed Web of Science ®Google Scholar
• Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015;193(3):921–926.
   PubMed Web of Science ®Google Scholar
• Batista JE, Kolbl H, Herschorn S, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015 Aug;7(4):167–179.
   PubMed Web of Science ®Google Scholar
• Yamaguchi O, Kakizaki H, Homma Y, et al. Safety and efficacy of mirabegron as ‘add-on’ therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). BJU Int. 2015 Oct;116(4):612–622.
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015 May;193(5):1572–1580.
   PubMed Web of Science ®Google Scholar
• Stief CG, Porst H, Neuser D, et al. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol. 2008 Jun;53(6):1236–1244.
   PubMed Web of Science ®Google Scholar
• Dell’Atti L. Efficacy of Tadalafil once daily versus Fesoterodine in the treatment of overactive bladder in older patients. Eur Rev Med Pharmacol Sci. 2015 May;19(9):1559–1563.
   PubMed Web of Science ®Google Scholar
• Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther. 1995 Aug;274(2):1014–1024.
   PubMed Web of Science ®Google Scholar
• Mariappan P, Alhasso A, Ballantyne Z, et al. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol. 2007 Jan;51(1):67–74.
   PubMed Web of Science ®Google Scholar
• Cornu JN, Merlet B, Ciofu C, et al. Duloxetine for mild to moderate postprostatectomy incontinence: preliminary results of a randomised, placebo-controlled trial. Eur Urol. 2011;59(1):148–154.
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, Von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol. 2012 Nov;62(5):834–840.
   PubMed Web of Science ®Google Scholar
• Maruyama I, Tatemichi S, Goi Y, et al. Effects of ritobegron (KUC-7483), a novel selective beta3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther. 2012 Jul;342(1):163–168.
   PubMed Web of Science ®Google Scholar
• Gray SL, Anderson ML, Dublin S, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015 Mar;175(3):401–407.
   PubMed Web of Science ®Google Scholar